MOSPD2 and nasopharyngeal carcinoma: Although in the present research we identified MOSPD2 as an EBV-miR-BART-22 target in NPC cells, further study is still required to verify the correlation between MOSPD2 and EBV-miR-BART-22 expression and eventually correlate MOSPD2 expression with the clinical data in the tissue microarray containing the same specimens.